Drug interactions occur when one drug affects the activity of another drug when both are administered together. They can increase toxicity, reduce efficacy, or produce unexpected effects. Identifying and managing drug interactions is critical for safe prescribing.
Types of Drug Interactions
Pharmacokinetic Interactions
Pharmacokinetic interactions occur when one drug affects the absorption, distribution, metabolism, or excretion of another drug. Metabolism interactions are the most common and clinically significant.
CYP450 enzyme induction occurs when one drug increases the production of CYP enzymes, accelerating the metabolism of other drugs. This reduces the concentration and efficacy of the affected drug. Inducers include rifampin (potent inducer of CYP3A4, 2C9, 2C19 — affects multiple drug classes), carbamazepine, phenytoin, phenobarbital, St. John’s wort (induces CYP3A4 and P-glycoprotein), and chronic alcohol use (induces CYP2E1). The effect takes days to weeks to develop and persists for days to weeks after discontinuation.
CYP450 enzyme inhibition occurs when one drug blocks CYP enzyme activity, reducing the metabolism of other drugs and increasing their concentration (risk of toxicity). Inhibitors include azole antifungals (ketoconazole — potent inhibitor of CYP3A4), macrolide antibiotics (erythromycin, clarithromycin — CYP3A4 inhibitors; azithromycin does not inhibit), cimetidine (pan-CYP inhibitor), amiodarone (CYP2C9 — increases warfarin levels), fluoxetine/paroxetine (CYP2D6 inhibitors), grapefruit juice (CYP3A4 inhibition in the gut wall — affects drug absorption, not systemic clearance), and acute alcohol use (inhibits CYP2E1). The effect develops within 1-3 days and resolves as the inhibitor is cleared.
P-glycoprotein is a drug efflux transporter that limits the absorption of drugs from the GI tract and restricts penetration into the brain. Inducers (rifampin, St. John’s wort) reduce absorption and CNS penetration of P-gp substrates. Inhibitors (verapamil, amiodarone, clarithromycin, ketoconazole) increase absorption and CNS penetration. Digoxin is a P-gp substrate — P-gp inhibitors increase digoxin levels, risking toxicity.
Pharmacodynamic Interactions
Pharmacodynamic interactions occur when two drugs have additive, synergistic, or antagonistic effects at the same receptor site or physiologic system.
Additive interactions occur when two drugs with the same effect produce a combined response that is the sum of their individual effects. Examples: alcohol + benzodiazepine (additive CNS depression can be fatal), NSAIDs + anticoagulants (additive bleeding risk), multiple antihypertensives (additive blood pressure reduction — desired in therapy but risk of hypotension), and anticholinergics + TCAs (additive anticholinergic effects — urinary retention, constipation, confusion).
Antagonistic interactions occur when one drug blocks the effect of another. Examples: naloxone + opioids (receptor antagonist reverses opioid effects), beta-blockers + beta-agonists (antagonism at beta-receptors), and SSRIs + MAOIs (antagonistic, but the more concerning issue is serotonin toxicity).
Food-Drug Interactions
Food can affect drug absorption through direct binding (calcium in dairy binds tetracyclines and fluoroquinolones, reducing absorption — take these antibiotics on an empty stomach or 2 hours apart from dairy), gastric pH changes (food increases gastric pH, reducing absorption of weakly acidic drugs like ketoconazole), competition for absorption (high-fat meals increase absorption of lipophilic drugs — griseofulvin, isotretinoin), delayed gastric emptying (slows absorption of many drugs, but this is usually not clinically significant for chronic dosing), and specific nutrient interactions (vitamin K-rich foods antagonize warfarin — consistent intake is more important than avoidance; tyramine-rich foods require avoidance during MAOI therapy to prevent hypertensive crisis).
Clinically Significant Interactions
Warfarin Interactions
Warfarin is one of the most interaction-prone drugs due to its narrow therapeutic index and CYP2C9 metabolism. Drugs that increase warfarin effect (INR increase, bleeding risk) include amiodarone, fluconazole, metronidazole, TMP-SMX, ciprofloxacin, levofloxacin, NSAIDs, and many others. Drugs that decrease warfarin effect include vitamin K (dietary or supplements), carbamazepine, phenytoin, rifampin, and St. John’s wort. INR should be monitored closely when any drug is added, discontinued, or changed in a patient on warfarin.
Statin Interactions
Simvastatin and lovastatin are metabolized by CYP3A4 — potent CYP3A4 inhibitors (erythromycin, clarithromycin, azole antifungals, cobicistat, grapefruit juice) increase the risk of myopathy and rhabdomyolysis. Atorvastatin is also CYP3A4 metabolized but at lower risk. Pravastatin, rosuvastatin, and pitavastatin are not significantly metabolized by CYP3A4 and have fewer drug interactions. Gemfibrozil, when combined with statins (especially rosuvastatin and cerivastatin — the latter was withdrawn) increases the risk of myopathy — fenofibrate is safer in combination.
Methotrexate Interactions
Methotrexate is renally excreted — NSAIDs, probenecid, and penicillin reduce its renal clearance, increasing the risk of myelosuppression and hepatotoxicity. TMP-SMX adds to folate antagonism, increasing myelosuppression risk.
Lithium Interactions
Lithium levels are increased by NSAIDs (by 20-40%), ACE inhibitors, ARBs, thiazide diuretics (by 25-50% — through sodium depletion that increases proximal tubule reabsorption of lithium), and metronidazole. Lithium levels are decreased by theophylline, caffeine, and sodium loading.
Risk Factors for Drug Interactions
Patient factors include polypharmacy (5+ medications — risk increases exponentially), older age (reduced drug clearance, more concurrent medications, increased sensitivity to many drugs), renal or hepatic impairment, genetic factors (CYP2D6, CYP2C19, CYP2C9 polymorphisms), and medications with narrow therapeutic indices. Drug factors include drugs that are CYP substrates, inhibitors, or inducers; drugs with narrow therapeutic index (warfarin, digoxin, lithium, phenytoin, cyclosporine, aminoglycosides); and drugs that are P-gp substrates.
Prevention and Management
Key strategies include maintaining an accurate, complete medication list (including OTC drugs, supplements, and herbals); using drug interaction screening software; avoiding unnecessary polypharmacy; knowing the most important drug interactions (see clinically significant interactions above); starting with low doses and titrating slowly when adding a potentially interacting drug; monitoring drug levels (warfarin INR, lithium, digoxin, cyclosporine, anticonvulsants) when adding or removing interacting drugs; educating patients about drug interactions and when to report symptoms; and consulting a pharmacist or clinical pharmacologist for complex regimens.
Summary
Drug interactions are classified as pharmacokinetic (CYP450 induction/inhibition, protein binding displacement, P-gp transporter effects) and pharmacodynamic (additive, synergistic, antagonistic). The most clinically significant interactions involve warfarin, statins, methotrexate, and lithium. Prevention requires thorough medication reconciliation, awareness of high-risk drug combinations, appropriate monitoring, and patient education. Polypharmacy, older age, and narrow therapeutic index drugs increase interaction risk.